Monday, December 05, 2022

Upcoming COCA Call (Dec 8th): Multisystem Inflammatory Syndrome in Children (MIS-C) - Epidemiology, Case Definition, and Prevention


#17,152

While children and adolescents generally experience less severe disease with COVID than adults, they are not exempt from being infected, and a substantial number can experience serious, even life-threatening, illness and/or sequelae.

Often these severe impacts occur after the acute phase of their infection, sometimes masking their  cause.

Last month, in Neurology: Incidence of Epilepsy and Seizures Over the First 6 Months After a COVID-19 Diagnosis: A Retrospective Cohort Study, we looked study showing an increased risk in seizures and epilepsy following COVID infection. 

This increased risk was most pronounced in patients under the age of 16 and among those who were not hospitalized for their illnesses, showing that even mild illness can cause serious, and sometimes lasting, sequelae.

Four months ago we looked at an MMWR report on Post-COVID conditions in children and adolescents, and found that the risks of experiencing several rare conditions rose sharply following COVID infection. While the absolute risk of these complications remains low, the relative risk in some cases more than doubles.

But perhaps the most serious post-COVID sequelae for adolescents and children is Multisystem inflammatory syndrome (MIS). The CDC describes the syndrome.

What is MIS?

Multisystem inflammatory syndrome (MIS) can affect children (MIS-C) and adults (MIS-A). MIS is a rare but serious condition associated with COVID-19 in which different body parts become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs.

This syndrome was first identified in the spring of 2020, and prompted a CDC HAN (see CDC HAN: Multisystem Inflammatory Syndrome In Children (MIS-C)), and a COCA call (see Multisystem Inflammatory Syndrome in Children (MIS-C)) in May of that year.

We've revisited the topic a number of times since then, including:



As of the end of November 2022, more than 9,000 children and adolescents in the United States have been diagnosed with MIS-C, and 74 deaths have been reported.  Like with pediatric influenza deaths, this is likely an undercount. 



On Thursday (Dec 8th) the CDC will hold a one-hour COCA Call for clinicians on MIS-C, and review a recently revised CSTE 2023 MIS-C case definition. These presentations are often technical, and are of greatest interest to clinicians and healthcare providers, but also may be of interest to the general public.

As always, If you are unable to attend the live presentation, these (and past) webinars are archived and available for later viewing at this LINK.

Details on this week's presentation follows:

Updates on Multisystem Inflammatory Syndrome in Children (MIS-C): Epidemiology, Case Definition, and Prevention

Overview

The Council of State and Territorial Epidemiologists (CSTE) and the Centers for Disease Control and Prevention (CDC) have developed a new multisystem inflammatory syndrome in Children (MIS-C) surveillance case definition to help reduce misclassification and complexity. This CDC/CSTE MIS-C surveillance case definition is based on an extensive review of data from 2020–2022. MIS-C is a rare, but severe condition that may occur 2-6 weeks after acute SARS-CoV-2 infection. CDC has been actively involved in MIS-C surveillance, public health investigations, and development of resources to support the public health and healthcare community. The updated CSTE/CDC MIS-C case definition will become effective on January 1, 2023.

During this COCA Call, presenters will review MIS-C epidemiologic and clinical trends, provide a rationale and description of changes in criteria for the new CSTE/CDC MIS-C surveillance case definition compared with the 2020 CDC MIS-C case definition, and discuss information relating to MIS-C and COVID-19 vaccination.

Presenters

Angela Campbell, MD, MPH, FAAP, FPIDS, FIDSA
Medical Officer
Severe Respiratory Illness and Multisystem Inflammatory Syndrome (SIM) Team Lead
Epidemiology Branch
Coronavirus and Other Respiratory Viruses Division (proposed)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Michael Melgar, MD
Medical Officer
Severe Respiratory Illness and Multisystem Inflammatory Syndrome (SIM) Team
Epidemiology Branch
Coronavirus and Other Respiratory Viruses Division (proposed)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Anna Yousaf, MD
Medical Officer
Severe Respiratory Illness and Multisystem Inflammatory Syndrome (SIM) Team
Epidemiology Branch
Coronavirus and Other Respiratory Viruses Division (proposed)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Call Materials

None at this time.

Call Details

When:
Thursday, December 8, 2022,
2:00 PM – 3:00 PM ET

Webinar Link:
https://www.zoomgov.com/j/1610894085

Webinar ID: 161 089 4085

Passcode: 510428

Telephone:
US: +1 669 254 5252 or +1 646 828 7666 or +1 669 216 1590 or +1 551 285 1373

One-tap mobile:
US: +16692545252,,1610894085#,,,,*510428# or +16468287666,,1610894085#,,,,*510428#

International numbers
Posted by at